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Abstract
Prostate biopsy is the current gold-standard procedure for prostate cancer diagnosis. Existing prostate
biopsy procedures have been mostly focusing on detecting cancer presence. However, they often
ignore the potential use of biopsy to estimate cancer volume (CV) and Gleason Score (GS, a cancer
grade descriptor), the two surrogate markers for cancer aggressiveness and the two crucial factors
for treatment planning. To fill up this vacancy, this paper assumes and demonstrates that, by optimally
sampling the spatial patterns of cancer, biopsy procedures can be specifically designed for estimating
CV and GS. Our approach combines image analysis and machine learning tools in an atlas-based
population study that consists of three steps. First, the spatial distributions of cancer in a patient
population are learned, by constructing statistical atlases from histological images of prostate
specimens with known cancer ground truths. Then, the optimal biopsy locations are determined in a
feature selection formulation, so that biopsy outcomes (either cancer presence or absence) at those
locations could be used to differentiate, at the best rate, between the existing specimens having
different (high v.s. low) CV/GS values. Finally, the optimized biopsy locations are utilized to estimate
whether a new-coming prostate cancer patient has high or low CV/GS values, based on a binary
classification formulation. The estimation accuracy and the generalization ability are evaluated by
the classification rates and the associated receiver-operating-characteristic (ROC) curves in cross
validations. The optimized biopsy procedures are also designed to be robust to the almost inevitable
needle displacement errors in clinical practice, and are found to be robust to variations in the
optimization parameters as well as the training populations.
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1. Introduction
1.1. The Need for Estimating Surrogate Markers for Cancer Significance
In an aging population, prostate cancer continues to be the second leading cause for cancer-
related death in American men. In the year 2008 alone, the American Cancer Society estimated
186,320 incidences and 28,660 mortalities of prostate cancer in the United States [1]. The
disparity between cancer incidence and the associated mortality rates implies that, although
prostate cancer is the most common cancer in US men, only a small proportion of prostate
cancer cases will be life-threatening [22]. Those life-threatening prostate cancers are often
known as “clinically-significant” prostate cancers, which are loosely defined as cancers that
are rapidly growing, aggressively infiltrating the surrounding normal tissue and/or highly likely
to spread to other parts of the body [3,43,44]. Indeed, clinical significance of prostate cancer
is the primary factor for clinical decision-makings: those patients with clinically-significant
prostate cancer should be followed with immediate treatment; whereas those with clinically-
insignificant prostate cancer should be only followed with watchful waiting. Therefore,
accurate evaluation of cancer significance becomes crucial for effective cancer management.
Evaluation of cancer significance is a challenging task, since it requires accurate identification
of prostate cancer and accurate assessment of cancer spatial extent. Generally, cancer
significance can be evaluated either directly or indirectly; while the direct way is ideal, it is
the indirect way that is more practical and that we will follow in this paper. Actually, the direct
way is to carefully examine the cancer prognosis in a series of longitudinal follow-ups.
However, this is often impractical, mostly due to its long study time and high clinical cost, and
due to the lack of a diagnostic tool that can accurately identify cancer in vivo. In the absence
of longitudinal follow-ups, clinical practice often follows the indirect way – to estimate certain
surrogate markers at one time instance, and use the estimated surrogate markers to indirectly
evaluate cancer significance. The commonly-used surrogate markers include cancer volume,
stage, grade, age, genetic factors and ethnic factors. Of those, two surrogate markers are perhaps
most important: cancer volume and Gleason Score (a cancer grade descriptor scored 2–10,
higher score indicating more aggressive cancer and worse prognosis [19]). This paper follows
this indirect way of evaluating cancer significance and aims to improve the estimation accuracy
for cancer volume (CV) and Gleason Score (GS), the two most important surrogate markers.
1.2. Existing Methods
Currently, estimation of CV and GS relies on either imaging techniques (e.g., [18,2,10,25]) or
biopsy procedures (e.g. [24,44,27,7,45,42,49]). Although imaging techniques, especially the
fast-evolving magnetic resonance imaging (MRI), have the advantage in their non-invasive
nature, they suffer greatly from the modest sensitivity and specificity, a drawback that is
commonly recognized in the prostate imaging literature (e.g., [25,28]). In the absence of an
imaging modality that could accurately and reliably diagnose prostate cancer at the current
stage, prostate biopsy continues to be the standard procedure for estimating CV/GS. Generally,
biopsy estimates CV/GS by sampling the prostate at a number of locations via biopsy needles.
The biopsy-sampled prostate tissue then undergoes microscopic examinations, revealing
cancer presence/absence and cancer pathology. However, as addressed below, using existing
biopsy procedures to estimate CV/GS is often limited in two respects.
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First, the sampling locations in the current biopsy procedures are often suboptimal. In most
biopsy procedures, the sampling locations are determined in a random or empirical manner,
leading to mis-detection of cancer and mis-estimation of surrogate markers [30,14]. To cope
with that, several computer-assisted approaches (e.g., [45,42,49]) have been developed. Their
approaches maximized the probability of biopsy needles to intersect with cancerous tissue, and
hence remarkably improved the detection of cancer presence. However, they are not necessarily
optimal for the estimation of surrogate markers like CV and GS, since for the estimation of
CV/GS, the limited number of biopsy needles has to not just intersect with cancerous tissue,
but also represent the spatial extent and pattern of cancer in the whole prostate. This
requirement renders the use of biopsy for CV/GS estimation fairly challenging.
Second, the traditional criteria for surrogate marker estimation are often suboptimal. For
estimating CV, the traditional criterion is the percentage of positive biopsies (e.g. [40]) – more
positive biopsies needles indicate larger cancers. This criterion, although quite intuitive, may
fail in certain circumstances. As illustrated in Fig. 1, it will incorrectly yield the same
percentage of positive biopsies (2 out of 6 in this case) for two prostates whose CV values are
substantially different. A possible solution to this problem would be increasing the number of
sampling locations, as suggested in [44,46], but that would substantially increase patient pain,
and moreover it might increase our risk of detecting clinically-insignificant prostate cancers,
leading to unnecessary treatment and all pertinent side effects [27]. For estimating GS, on the
other hand, the traditional criterion is to analyze the limited number of prostate tissue samples
extracted by biopsy, find out two most common glandular cancer patterns from those limited
tissue samples, assign to each of them a Gleason Grade (ranging from 1–5) and subsequently
add the two Gleason Grades together [19]. However, several studies (e.g. [8,31]) pointed out
that the biopsy estimated Gleason Score (usually known as “clinical Gleason Score”, or cGS)
is often different from the actual Gleason Score obtained after the prostate removal (usually
known as “pathological Gleason Score”, or pGS). In other words, using biopsy-extracted cGS
to estimate the actual pGS is subject to mis-estimations. And worse, such mis-estimation might
be substantial in a considerable proportion of cases [26]. To minimize mis-estimations for both
CV and GS, an ideal estimation criterion should comprehensively consider the biopsy
outcomes from all biopsy locations, in a sophisticated, perhaps highly non-linear way that could
effectively reflect the spatial pattern of cancer. Actually, this novel, cancer-spatial-pattern-
based estimation criterion is one of the major contributions in our study, as will be addressed
later in this section.
1.3. The Proposed Method
This paper presents optimized biopsy procedures specifically designed for estimating cancer
volume (CV) and Gleason Score (GS), two of the most important surrogate markers for the
clinical significance of prostate cancer. In our study, the estimation for CV/GS is binary (high
v.s. low) instead of continuously-valued, so as to better relate to the clinical decisions that tend
to be binary: immediate treatment for CV/GS values above certain clinical threshold, or
“watchful waiting” otherwise.
Our approach assumes that, prostate cancers having different (high v.s. low) CV/GS values
may exhibit different spatial patterns, which could be properly sampled by optimally-placed
biopsy needles. By “spatial pattern”, we mean spatial distribution of cancer reflected by the
biopsy outcomes at all sampling locations. For instance, if we order the biopsy locations in
Fig. 1 from base to apex, right to left, and denote the biopsy outcome at each biopsy location
to be 1 for cancer positive and 0 otherwise, we will observe spatial cancer pattern of [1 0 0 0
0 1] for the first patient and [0 1 1 0 0 0] for the second patient. In this way, CV values of those
two patients could be effectively estimated/differentiated, because the pattern of two positive
biopsies next to each other (in the second patient) most probably implies cancer distributed in
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a larger, connected area than the pattern of two positive biopsies far apart (in the first patient).
Actually, as will be demonstrated both qualitatively in Section 2.3 and quantitatively in Section
3.2, the spatial pattern of cancer is a robust estimation criterion with consistent high estimation
accuracy in the population under study.
Based on the assumption of using spatial cancer pattern for estimation, our approach combines
image analysis and pattern classification tools in a statistical atlas-based population study. To
learn the differences of spatial cancer patterns between the subpopulations having different
(high v.s. low) CV/GS values, our approach first constructs statistical cancer atlases from
histological images of a cohort of surgically-extracted prostate specimens. Then, the optimal
biopsy locations are determined in a feature selection formulation, so that biopsy outcomes
(either cancer presence or absence) at those locations could altogether differentiate between
the subpopulations of high and low CV/GS specimens at the best rate. The optimized biopsy
locations are thereafter used to estimate whether a new-coming prostate cancer patient has high
or low CV/GS values, in a SVM-based binary classification formulation. The estimation
accuracy and the generalization ability of our approach are evaluated by the classification rates
and the associated receiver-operating-characteristic (ROC) curves in cross validations.
Compared with optimized biopsy procedures previously developed in [45,42,49], our approach
has the following three merits. The first and foremost merit lies in the objective: previous ones
aim to improve the detection of cancer presence; ours aims to estimate surrogate markers for
the clinical significance of prostate cancer, which is a far more important yet far more difficult
problem. Detecting cancer presence, the objective in their studies, requires that at lease one
biopsy needle intersects with cancer; whereas estimating surrogate markers, the objective in
our study, has an additional requirement – it requires biopsy needles to sample the prostate in
a way that can reflect the spatial cancer patterns. The second merit is the high generalization
ability in our approach. The high generalization ability stems from the sparsity of SVM in the
feature selection and pattern classification formulations; it also arises from using the novel,
more reliable spatial-pattern-based estimation criterion in the classification formulation. The
third merit of our approach is its robustness to the almost inevitable uncertainties of needle
placement in clinical practice. The robustness is obtained by selecting optimized biopsy
locations that have high estimative powers not only at themselves but also in their
neighborhoods. Moreover, unlike many optimization processes, whose performances are
heavily dependent on the optimization parameters being used, our biopsy optimization process
is relatively stable in terms of estimation accuracy, regardless of the variations in the
optimization parameters and the training populations, as will be shown in the sensitivity
analysis in Section 4.
The remainder of this paper is organized as follows. Section 2 details our framework. Section
3 shows the results for the optimized biopsy procedures and their estimation/classification
accuracies. Section 4 examines the robustness of our framework with regard to the variations




As sketched in Fig. 2, our approach consists of three components: atlas construction (via image
registration), biopsy location optimization (via feature selection) and surrogate marker
estimation based on the optimized biopsy locations (via binary classification). Those three
components are elaborated in the subsequent Sections 2.3–2.5. Prior to that, we will first
describe data acquisition in Section 2.2.
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We have collected a population of 83 prostate specimens {pn|n = 1, 2, …, N} (N = 83) that
have undergone radical prostatectomy (a surgery for prostate removal). These specimens are
available from the tissue bank of the Center for Prostate Disease Research (CPDR)
(http://www.cpdr.org). They are aged 60.4±6.3 years old (min 44, max 73), with pre-biopsy
prostate-specific antigen (PSA) values at 12.59 ± 18.52 ng/mL (min 0.7, max 138), and the
actual prostate sizes at 92.7±41.1 grams (min 46, max 165, 1 gram in weight is approximately
equal to 1 cc in volume).
Those specimens are further divided into different subpopulations, according to surrogate
marker values that are known from pathological analysis. When different surrogate marker is
used, the subpopulation division might be different. Specifically, when CV/GS is the surrogate
marker under estimation, those specimens are divided into a subpopulation of 46/47 specimens
with high CV/GS and the remaining 37/36 with low CV/GS. Here, the thresholds of 0.5cc for
CV and 6 for GS are adopted from clinical conventions. After the division, each specimen pn
is assigned with a class label C(pn),
(1)
As shown in Table 1, the subpopulation divisions have uncovered three interesting facts that
are worth noting. First, almost one quarter of the specimens have low CV and low GS, an
indication that their cancers might be clinically-insignificant. This is a fundamental issue in
clinical practice: some patients may be detected with cancer by repeated biopsies; however,
their cancers might be insignificant so that they should not be followed with prostatectomy.
This fact underlines the importance of estimating their surrogate markers and clinical
significance as what we are discussing in this paper. Second, being high in one surrogate marker
does not necessarily indicate being high in the other (19.3% has high GS but low CV, while
18.1% has low GS but high CV). Therefore, the class labels for a same specimen might be
different when different surrogate markers are under estimation. For the same reason, different
atlases and different optimized biopsy procedures are needed for estimating different surrogate
markers. Third, overall, the prostate specimens having high and low surrogate markers in our
study are almost half and half (or, more accurately, 56% and 44%), so the dataset is not
noticeably biased when it is used to reflect different cancer patterns in subpopulations having
different CV/GS values.
To also present pathologists-defined cancer ground truth, histological images have been
collected for all specimens. During the histology collection, each specimen was whole-
mounted, step-sectioned at 2.25mm intervals and H/E stained at 5 μm thickness, leading to
series of 2D histological slices with pathologically-defined cancer ground truth (e.g. red regions
in Fig. 3); then, the series of 2D histological slices were reconstructed into a 3D histological
image, which will be used to reveal 3D cancer distributions in the subsequent atlas
constructions.
2.3. Constructing Statistical Atlases
From those acquired population data, our study first constructs statistical atlases to observe the
different cancer spatial patterns from subpopulations having different surrogate marker values.
This will provide qualitative support for using the spatial pattern of cancer as a reliable
estimation criterion. Generally, a statistical atlas is a model of the object/organ of interest,
usually represented as the probability of certain anatomic structure or certain types of tissue
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(in our paper, cancerous tissue) being present at each voxel in the 3D coordinate system [42,
15,37,9].
Basis to the atlas construction is to spatially normalize the 3D histological images across
specimens into a common prostate space S, which has regular shape and has 256 × 256 × 124
image voxels. The spatial normalization is done by a 3D surface-based non-rigid image
registration method [41]. Fig. 3 shows the common prostate space and a typical histological
image before and after the spatial normalization, in both 3D and 2D views. The spatial
normalization preserves the zonal anatomy of the prostate, as demonstrated in [49], so that
after normalization, the same spatial coordinates will correspond to approximately the same
anatomic locations across specimens.
Then, the statistical cancer atlases are constructed by merging the spatially-normalized
histological images for each subpopulation. Results are shown in Fig. 4. In the atlases, the
brightness of each voxel represents the probability of cancer occurrence in the subpopulation
of interest. From visual inspections, it is not difficult to observe that, statistically,
subpopulations having different surrogate marker values do exhibit different spatial patterns
(distributions) of caner. Moreover, some candidate biopsy locations (e.g., blue dots in Fig. 4)
can be intuitively observed, since biopsy outcomes (either cancer positive or negative) at those
locations would most probably differentiate between different subpopulations. How to
automatically and accurately select the optimal biopsy locations is described in the following
sub-sections.
2.4. Determining Optimal Biopsy Locations by Feature Selection
In this section, the problem of selecting optimal biopsy locations is converted to a feature
selection formulation. Basis to this conversion is the feature extraction step, which connects
each potential biopsy location in the common prostate space with a feature in the feature space.
2.4.1. Feature Extraction: Connecting Each Potential Biopsy Location to a
Feature—A potential biopsy location u ∈ S ⊂ ℜ3 is connected to a feature B(u), provided
that B(u) is the “biopsy outcome” of the biopsy needle centered at location u. This connection
is further explained below.
Mathematically, a biopsy needle can be modeled as a semi-cylinder Q(O),
(2)
where O = (Ox, Oy, Oz) ∈ ℜ3 is the center, r is the base radius and l is the semi-length of the
semi-cylinder (c.f. Fig. 5). Since r = 1.5mm and l = 6mm are usually determined from clinical
conventions, the semi-cylinder shaped biopsy model has only one parameter – the center O.
When this semi-cylinder shaped biopsy needle is centered at a potential biopsy location u ∈
S ⊂ ℜ3, it will extract a piece of prostate tissue also centered at u. From an image analysis
point of review, the extracted piece of prostate tissue can be modeled as
(3)
This piece of prostate tissue will exhibit either cancer presence or cancer absence, denoted as
“biopsy outcome” B(u),
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In this way, each specimen pn can be represented by a high-dimensional feature vector F(pn;
{u1, u2, …, uM}), i.e.,
(5)
where u1, u2, …, uM are all possible biopsy locations, with M being the total number of them.
The connection between each potential biopsy location and a feature is also illustrated in Fig.
6.
2.4.2. Feature Selection: Finding Optimized Biopsy Locations—After connecting
each potential biopsy location u with a feature B(u) in the feature extraction step, it naturally
follows that the problem of selecting K optimal biopsy locations {us1, us2, …, usK} in the
common prostate space S can be translated to the selection of a subset of K best features {B
(u{s1}), B(u{s2}), …, B(u{sK})} in the feature space, i.e.,
(6)
such that under certain classifier whose decision function is Z[·], the classification result Z[f
(pn; {s1, s2, …, sK}] could agree with pre-known class label C(pn) at the best rate, for all
specimens n = 1, 2, …, N, i.e.,
(7)
Here f (pn; {t1, t2, …, tK}) denotes the biopsy-extracted multivariate information (spatial-
pattern-vector) at those K locations {t1, t2, …, tK} from training prostate specimen pn.
2.4.3. Solving the Feature Selection Problem—Selecting K out of M features is a
challenging task when we have K ≪ M in our problem. Indeed, K, the number of optimal
biopsy locations, is typically ranged from 6 to 12 (keep in mind that, in order to reduce patient
pain and the biopsy-induced morbidities, a small K value is usually preferred). Meanwhile,
when the image space is discretized, M, the total number of all possible biopsy locations, is
usually in the millions.
Feature selection methods have been extensively investigated in the machine learning
community. Their common purpose is often to determine a small number of optimal features
for increasing both the accuracy and the generalization ability of classification. During the past
two decades, a variety of methods have been developed for feature selection, such as Adaboost
[16] and decision trees [38]. In [20], Guyon and Elisseeff summarized that the most frequently
used feature selectors can be broken down into two types: feature ranking and subset selection.
They both have merits and drawbacks. Particularly, feature ranking methods rank features
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according to their individual predictive powers and simply pick up a number of top-ranked
features – this type of methods are computationally economic, but will often lead to highly
sub-optimal solutions, as they do not evaluate the statistical correlations among features. Subset
selection methods, on the other hand, select a subset of features that altogether have the highest
predictive power – this type of methods will lead to globally optimal solutions, but are often
time-consuming or even computationally prohibitive when the total number of features is large,
as in our case. In practice, these two types of feature selectors are often jointly used: to initialize
with feature ranking and to refine with subset selection. We adopt this two-step strategy in our
approach.
Step 1: Feature Ranking: Features are first ranked by their individual estimative powers. The
estimative power of the ith feature (hence the potential biopsy location ui) is measured by the
Pearson's correlation coefficient with class labels C(pn) across all specimens pn(n = 1, 2, …,
N), i.e.,
(8)
Here  is the mean biopsy outcome at location ui across all specimens and
 is the mean class label across all specimens. A higher correlation coefficient
ρ(·) represents stronger estimative/discriminative power, since agreement of the biopsy
outcome at a given location with the known class label of more specimens implies that this
given location has higher estimative value for class labels. Out of the total of M features, this
step will select m top-ranked features (K < m ≪ M). The value of m is experimentally found
having little influence to the final estimation/classification rate as long as m > 4K is satisfied.
Note that, to account for the almost inevitable needle placement errors within an expected range
in clinical practice, features (hence biopsy locations) should be selected if they have high
estimative powers not only at themselves, but also at their neighborhoods. Therefore, a high
ranking (or a high estimative power) does not necessarily guarantee a feature (or a biopsy
location) to be selected; rather, we would prefer the ith biopsy location by seeking
(9)
where Θ(uj) denotes the neighborhood of a potential biopsy location uj and | · | is the cardinality
of a set. The first term in Eqn. 9 represents high estimative power in the candidate feature
(biopsy location) itself, and the second term represents necessarily high estimative power in
the neighborhood.
Step 2. Subset Selection: Within the reduced number of features, subset selection method can
be used to select a subset of features that altogether has the highest estimative power. We have
used a support vector machine (SVM)-based subset selector, which selects subset of features
through iterative backward sequential elimination (BSE) and forward sequential inclusion
(FSI) of features [13]. In each iteration, the BSE (or FSI) procedure removes (or adds) one
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feature that minimizes the Gaussian-kernel SVM-based leave-one-out error bound [39],
compared with removing (or adding) other features. The leave-one-out error bound is known
as an unbiased estimator for the generalization ability of a classifier trained on all but one
available samples, which is 4R2‖w‖2 for SVM, where R is the radius of the smallest hyper-ball
containing all mapped feature vectors by some kernel function Φ(·, ·), and w is the normal
vector to the separation hyper-plane in the SVM formulation. The algorithm stops when there
is no better feature to be removed or added into the subset. The output is the set of K optimal
features, and hence the K optimal biopsy locations {us1, us2, …, usK}, which, as a whole, have
the highest estimative/discriminative power.
2.5. Estimating Surrogate Markers by Classification
The optimal biopsy locations determined in the population of prostate specimens are then used
to estimate whether a new-coming prostate cancer patient has high or low surrogate marker
values. Note that, in this paper, the surrogate marker estimation problem is formulated as a
binary classification problem rather than a more intuitive continuous-valued regression
problem, because the binary estimation results better relate to the clinical decisions that tend
to be binary: immediate treatment for CV/GS above some clinical thresholds, or “watchful
waiting” otherwise.
Actually, the real application of the optimized biopsy procedures requires warping/mapping
the optimized locations from histological image space of the population into the intra-operative
transrectal ultrasound (TRUS) or MR image space of the specific patient under biopsy. Such
a registration should be deformable and multi-modal (histology-TRUS/MRI). Furthermore,
since histological images used in this paper contain prostate only, whereas the intra-operative
TRUS or MR images usually contain prostate as well as all the surrounding tissue/organs, it
would be plausible to segment the prostate from the intra-operative TRUS/MR images prior
to the registration. The segmentation can be obtained by a 3D deformable model that was
previously developed in our group [48]. After segmentation, we can register the prostate
surfaces between histological and TRUS/MR images using the same deformable surface
matching method [41] as we used to register multiple histological images in the atlas
reconstruction part; or, we can register prostate from histological and TRUS/MR images by
more accurate voxel-wise attribute matching methods that are recently developed in our group
[35,36,50]. Since the prostate segmentation and histology-TRUS/MRI registration algorithms
are beyond the scope of this paper, we thereafter simplify the real biopsy application problem
by assuming that the optimized biopsy locations have already been warped to the specific
patient under biopsy, and those optimized biopsy locations are still denoted as {us1, us2, …,
usK}.
When a new-coming patient is under examination, a number of K needles will be placed at the
optimized biopsy locations {us1, us2, …, usK}. Biopsy outcomes from those locations can be
stacked into a multivariate vector [B(us1), B(us2), …, B(usK)], representing spatial pattern of
cancer. Based on the biopsy-extracted cancer spatial patterns, this patient could be estimated/
classified to have high or low surrogate markers by an appropriate pattern classifier.
Theoretically any pattern classifier can be used for estimation/classification, such as artificial
neuron network, naive Bayesian classifier, multivariate discriminant [51] and support vector
machine (SVM) [5]. We have used the non-linear SVM classifier based on the Gaussian kernel
function . Generally, SVM is a supervised classifier that divides the
two classes of training samples by a separation hyper-plane that maximizes the margin distance
between the two classes [5]. When the linear SVM is used, the separating hyper-plane resides
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in the original feature space; whereas on the other hand, when non-linear SVM is used, the
separating hyper-plane resides in the mapped feature space (Hilbert space).
We chose SVM because of three reasons. First, SVM has been empirically demonstrated as
one of the most powerful and computationally efficient pattern classifier, with successful
applications in numerous clinical problems like ours [4,6,17,21,32,33,47]. Second, since our
feature selection is SVM-based, a coupled classification that is also SVM-based could probably
achieve the highest accuracy. Third, SVM classifier can improve the generalization ability of
our approach, because of its implicit sample selection mechanism and the sparsity
characteristics. This is especially suitable for our study when the number of features (M) is far
greater than the number of training samples (N).
3. Results
3.1. Optimized Biopsy Procedures
The results for the optimized biopsy procedures are shown in Fig. 7. Following clinical
conventions, biopsy needles are placed into the prostate in either transrectal (posterior to
anterior insertion) or transperineal (apex to base insertion) settings. Different procedures are
optimized for estimating different surrogate markers, for the reason that being high in one
surrogate marker does not necessarily imply high in the other, as can be observed in Table 1.
In contrast to existing biopsy procedures (e.g., [7,12,14,24,45,42,49]), the biopsy needles in
our optimized procedures are ordered according to their importance/priority, so as to better
delineate the spatial patterns of cancer. In the upper-left subfigure of Fig. 7, the actual physical
distance between the center of the 1st and the 4th needles is 18.44mm, and the distance between
the 3rd and the 4th needles is 15.42mm, almost ten times of the radius of the needle.
To gain more understanding of how the optimized procedures are used to estimate, for instance,
CV, we can visually superimpose the optimized transrectal procedure in the upper left part of
Fig. 7 onto the statistical atlases of high and low CV specimens in the top row of Fig. 4. Then
we can observe that, specimens having high CV values tend to have positive biopsies at the
1st, 2nd and 4th biopsy locations, while specimens having low CV values do not. Similar
observations could be drawn for estimating GS values.
All experiments were operated in C code on a 2.8 G Intel Xeon processor with UNIX operation
system. In constructing the statistical atlases, it took 26 hours to normalize all 83 specimens
onto the common prostate space (about 25 minutes each), which could be reduced to
approximately 3 hours by paralleling the processes on 8 CPUs. Another 1.5 hours is needed
for the optimization of biopsy locations and the subsequent binary classification. It is worth
noting that the relatively large computational cost is not a serious problem for clinical
applications, since both the statistical atlas construction and biopsy optimization are computed
offline rather than real-time.
3.2. Estimation Accuracy of the Optimized Biopsy Procedures
To evaluate estimation accuracy, our optimized biopsy procedures are applied to the collected
prostate specimens (the ones described in Section 2.2) with known surrogate marker values.
Both leave-one-out and ten-fold cross validations are carried out. That is, we train the optimized
biopsy procedures by all but one (or one-tenth) prostate specimens and test on the left-out one
(or one-tenth) specimen, repeating until every specimen (or every set of one-tenth of
specimens) has been left out once.
In cross validations, the estimation accuracy is measured by classification rates and the
associated receiver-operating-characteristic (ROC) curves. (Recall that the estimation problem
is formulated as a binary classification problem to accommodate to the clinical decisions that
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tend to binary). Mathematically, classification rate is the fraction of the prostate specimens that
have been correctly classified/estimated in terms of high v.s. low in surrogate marker values,
i.e.,
(10)
where 1(X) is the logic function that equals 1 when the event X is true and 0 otherwise,
ZSVM[f] is the SVM decision function which outputs a class label (“+1” for high and “−1” for
low surrogate marker value), based on the input feature vector f. In the ROC curve, the
relationship between the true positive rate (TPR) and false positive rate (FPR) are plotted. TPR
(also known as “sensitivity”) and FPR (also known as “1-specificity”) are defined as
(11)
Fig. 8 shows the estimation/classification accuracy and ROC curves for the leave-one-out cross
validations. The estimation/classification rates of 94.79% (or 81.93%) and the areas under ROC
curve (AUC) of 0.98 (or 0.83) have been observed, when estimating CV (or GS) by 7 optimized
needles in the transperineal setting. Similarly, when ten-fold cross-validation mechanism is
used, the classification rates for these two cases are 92.59% and 88.75%, demonstrating a good
generalization ability of our approach. More details of the estimation accuracy can be found
in Table 2 for different biopsy settings in estimating different surrogate markers.
In Fig. 8(A1&A2), the estimation/classification accuracies are also recorded when different
numbers of biopsy needles are optimized. An interesting finding is that, as long as more than
6 or 7 biopsy needles are optimized, there is no added value for additional number of biopsy
needles. This finding underlines the importance of optimizing biopsy locations other than
increasing the number of biopsy locations.
4. Sensitivity Analysis
Our framework is essentially an optimization problem in a population study – it optimizes
biopsy locations, and the optimum is defined on the collected population of prostate specimens.
Indeed, in most optimization systems or population studies like ours, a common problem is
that, the performance of the system or study is usually sensitive to the variations in the
optimization parameters or the input (training) populations. Those sensitive, or unstable,
estimators would obviously have limited clinical use. Therefore, the question herein is, whether
our framework is sensitive/unstable in these respects, and if it is, to which extent.
This section aims to evaluate the sensitivity of our framework with regard to two types of
variations that can potentially limit the generalization ability of our framework: 1) variations
in the optimization parameters and 2) variations in the training populations. They are described
in Sections 4.1 and 4.2, respectively.
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4.1. Effects of Variations in the Optimization Parameters
The effects of two major optimization parameters are examined in this section. The first major
parameter is the threshold T for the Pearson's correlation coefficient. This threshold T is
introduced to encourage statistical independence between any two features selected, and
therefore to avoid several needles being selected around a single location. That is, in the feature
ranking part (“Step 1” in Section 2.4.3), we eliminate those features that have high correlation
(>correlation threshold T) with the already selected top-ranked features, before we proceed to
select the next top-ranked feature. The second major parameter is the Gaussian kernel size σ
for the non-linear SVM. It is introduced in SVM-based feature selection and SVM-based binary
classification. Ideally, the estimation/classification accuracy of our optimized biopsy
procedures should be consistent/stable, regardless of the variations in the threshold T and the
SVM kernel size σ.
In our experiments, one parameter is fixed while the other varies, and the robustness of our
approach is demonstrated by the consistency in the resultant estimation/classification rates and
ROC curves, as shown in Fig. 9.
4.2. Effects of Variations in the Training Population
In any population-based study like ours, it is understandable that different populations of
subjects might yield different optimization results. The key question is to which extent.
To answer this question, we have simulated new populations of prostate specimens by a
statistical simulation method known as bootstrap [11,29]. In statistical inference, bootstrap
evaluates an estimator (e.g., estimation/classification rates in our case) of the original
population by simulating new populations via resampling the original population with
replacement [23]. “Resampling with replacement” means that, after choosing a prostate
specimen in the original population, we put it back before choosing the next specimen, until
we have picked up the same number of prostate specimens as that in the original population.
As a result, some prostate specimens will be selected multiple times while others not even
once. For instance, if we are considering an estimator (e.g., the mean value) from an original
population of natural numbers {10, 45, 20, 50, 38} and we want to establish a standard deviation
for the original estimator value, we could resample the original population with replacement
and thereby obtain an infinite number of simulated populations, such as {10, 20, 10, 38, 50},
{45, 20, 38, 45, 20}, and so forth. Each simulated population will yield one “simulated
estimator value” and a large number (usually greater than 10 times the sample size in the
original population) of such simulated estimator values will help us establish the standard
deviation for the original estimator value.
Using the bootstrap method, we have simulated 850 populations, each having the same number
(83) of specimens as the original population has and each leading to a cross-validated
classification rate, which altogether forms a bootstrapping distribution of 850 classification
rates, as shown in Fig. 10. This bootstrapping distribution reveals the mean classification rate
at 87.15% and the associated standard deviation at 5.79%. Small standard variations are also
found in transperineal/transrectal procedures for estimating CV/GS, prompting the robustness
of our framework with regard to the variations in the training population.
We chose bootstrap over Monte Carlo, another widespread simulation method because Monte
Carlo simulation generates new samples from a prior knowledge of the underlying sample
distribution, while bootstrap method simply re-samples the original samples without any prior
knowledge of the underlying sample distribution. Bootstrap simulation method is therefore
more suited in our study, since we don't have a good probabilistic cancer growth model for
generating new prostate cancer specimens.
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In this paper, we developed optimized biopsy procedures specifically designed to estimate
cancer volume (CV) and Gleason Score (GS), which are two of the most important surrogate
markers for clinical significance of prostate cancer. To the best of our knowledge, our study
is the first to present optimized biopsy procedures, as well as the novel estimation criterion,
that can be used to specifically estimate surrogate markers for cancer significance. We have
assumed and demonstrated that, by optimally sampling the spatial patterns of cancer, biopsy
procedures could be used to estimate/classify whether a prostate cancer patient has high or low
CV/GS values. In our framework, selecting the optimized biopsy locations is formulated as a
feature selection problem, where we selected biopsy locations such that biopsy outcomes from
those locations could best differentiate between specimens having different (high v.s. low)
surrogate marker values. Accordingly, estimating surrogate markers is formulated as a binary
classification problem, which estimates/classifies whether a new patient has high or low
surrogate marker values in a way that generalizes well. Moreover, our approach is designed
with the ability to account for the almost inevitable errors of needle placement in clinical
practice; it is also experimentally found to be robust with regard to the major parameters in our
optimization process and with regard to the input training populations.
In contrast to existing biopsy procedures, which mostly aim to improve the detection of cancer
presence, our study aims to estimate surrogate markers for clinical significance of prostate
cancer, which is a far more important yet far more difficult problem. For detecting cancer
presence in those existing procedures, it is required that at least one biopsy needle can intersect
with cancerous tissue; whereas for estimating surrogater markers, the goal in our study, it is
required that the multiple biopsy needles must sample the prostate in a way that can reflect
cancer spatial pattern. Because of this fundamental distinction, this paper has a completely
different formulation from the existing ones. As a result, our optimized biopsy procedures can
provide substantial information for the optimal treatment planning and effective cancer
management.
The surrogate marker estimation in this paper is binary (high v.s. low) instead of continuously-
valued, because the binary estimation better relates to the clinical decisions that tend to be
binary: immediate treatment for surrogate marker values above some clinical threshold, or
“watchful waiting” otherwise. Meanwhile, we have developed different biopsy procedures for
estimating different surrogate markers (CV or GS). Reasons can be found in Table 1: that being
high in one surrogate marker does not necessarily indicate high in the other. In occasions where
CV and GS do not agree with each other (in terms of high v.s. low), how to utilize the estimated
CV and GS values to evaluate clinical significance of prostate cancer becomes a quite
challenging problem. Actually, other than CV and GS, there are numerous other surrogate
markers that will also contribute to the determination of the clinical significance of prostate
cancer. Such surrogate markers include, but are not limited to, age, genetic factors and ethnic
factors. Kibel stated in [27]: “The 40-year-old patient with a 0.5 cc tumor is of much greater
concern than the 80-year-old with a 1.0 cc tumor.” Till recently, how to comprehensively use
all those surrogate markers to conclude the cancer significance is still a challenging problem
under debate [3,43]. Therefore, this paper only discusses estimations of surrogate markers CV
and GS, and the further evaluation of cancer significance goes beyond the scope of this paper.
Our study has yielded several interesting observations. Firstly, we have observed in Fig. 8
(A1&A2) that the increased number of biopsy needles over 6 or 7 does not provide added
estimative value, and should rather be avoided because of the marginal decrease in estimation
accuracy and the increase in patient pain as well as the associated morbidities. This provides
quantitative reference for the ongoing debate about how many needles are appropriate to
balance between patient pain and the detection of clinically-significant prostate cancers.
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Secondly, we have observed qualitatively in Fig. 8 and quantitatively in Table 2 that, the
estimation accuracy for cancer volume is noticeably higher than that for Gleason Score. A
plausible explanation could be that cancer volume is a quantity that is more closely correlated
to the spatial pattern of prostate cancer and could therefore be better sampled and estimated
by the optimally-placed biopsy needles. Generally, larger cancers are expected to have grown
closer to the capsule boundary than smaller cancers; therefore needles placed in those locations
would be more likely to determine whether a tumor is large or small with high accuracy. This
prompts future investigations, especially from the clinical perspective, of the correlations
between cancer spatial patterns and cancer surrogate markers.
The presented framework is general. It could thereby be readily applied to different
populations, different surrogate markers, different types of human cancer and even different
clinical procedures other than biopsy. For example, our framework could be potentially used
to find whether different patient groups (stratified by ethnicity, age or PSA level) tend to
develop clinically-significant prostate cancers at different locations on statistical basis.
Additionally, it could also be used to guide focal radiotherapy or other spatially-confined
treatments to those locations that are statistically more likely to develop clinically-significant
prostate cancer, thus increasing the treatment efficiency.
A potential limitation of our study is the relatively small sample size: 83 prostate specimens
might not be sufficient to accurately represent cancer distributions in the entire population of
prostate cancer patients. Actually, this limitation is inherent to any approach attempting to
derive cancer distribution (e.g., [45,42,49,34]). A possible solution would be to encourage
multi-institutional studies and data sharing processes, so that larger sample size could be
independently acquired and the “true” cancer distribution could be approximated with less bias.
Meanwhile, we are planning to validate our optimized biopsy procedures in new groups of
patients, initially via ex vivo biopsy of the surgically extracted prostatectomy specimens.
In summary, we have presented an approach to derive optimized biopsy procedures, for
estimating cancer volume and Gleason Score, two of the most important surrogate markers for
clinical significance of prostate cancer. More validations and inter-institutional collaborations
are expected in the future.
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A typical scenario where mis-estimation occurs when using the commonly-adopted estimation
criterion for CV. Black solid dots represent the biopsy locations in clinical routines. The red
regions represent prostate cancer regions. Please refer to text for more details.
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Systematic sketch for the general framework of our approach.
Ou et al. Page 18














The common prostate space (a) and the histological image of a typical specimen before (b) and
after (c) the 3D spatial normalization, in both 3D (top row) and 2D (bottom row) views. Red
regions are cancer ground truths labeled by pathologists. The bottom row shows the central
slice in the coronal orientation.
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Statistical atlases constructed from subpopulations having different (high v.s. low) surrogate
marker values. Blue dots represent intuitively-observed biopsy locations where different
subpopulations can be differentiated.
Ou et al. Page 20














Modeling a biopsy needle as a semi-cylinder. (a) A typical biopsy needle – when it is placed
into the prostate, the “cut-out” part will extract a piece of prostate tissue; (b) the cut-out part
of the biopsy is modeled as a semi-cylinder, with center O, base radius r and semi-length l.
The values of r = 1.5mm and l = 6mm are determined by clinical conventions.
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Feature extraction step connects each potential needle location uj with a feature B(uj). This
connection is the basis to the conversion of the problem of selecting optimal biopsy locations
into the feature selection formulation.
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Optimized biopsy locations for estimating cancer volume (top row) and Gleason Score (bottom
row), by using seven needles in both transrectal and transperineal settings.
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Estimation accuracy for CV (top row) and GS (bottom row), by the optimized biopsy
procedures in transperineal settings. (A1&A2): classification rate as a function of the number
of optimal needles. (B1&B2): ROC curve, where 7 needles were used.
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Robustness of our approach in estimating GS, with regard to the variations of two major
optimization parameters (threshold T and Gaussian kernel σ). (A) T is fixed at 0.5, and σ varies
from 1 to 50 (transperineal setting); (B) σ is fixed at 20, and T varies from 0.4 to 0.8 (transrectal
setting).
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Bootstrapping distribution of the classification rates in 850 simulated populations. The mean
and standard deviation is established at 87.18±5.79%, for using transperineal optimized
biopsies to estimate GS. Similar results are found in transperineal / transrectal biopsy
procedures when estimating CV/GS.
Ou et al. Page 26

























Ou et al. Page 27
Table 1
Number of specimens in the subpopulations having high or low CV/GS. The thresholds (0.5cc for CV and 6 for GS)
are adopted from clinical conventions.
High CV (≥0.5cc) Low CV (<0.5cc) Total
High GS (≥6) 31 (37.3%) 16 (19.3%) 47 (56.6%)
Low GS (<6) 15 (18.1%) 21 (25.3%) 36 (43.4%)
Total 46 (55.4%) 37 (44.6%) 83 (100%)
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Table 2
Estimation accuracy in the leave-one-out cross validations, in terms of classification rate and the area under the ROC
curve (AUC). Here, seven biopsy needles are optimized to estimate CV and GS, respectively.
Classification Rate AUC
For CV For GS For CV For GS
Transrectal Biopsy 93.75% 78.54% 0.96 0.79
Transperineal Biopsy 94.79% 81.93% 0.98 0.83
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